-+ 0.00%
-+ 0.00%
-+ 0.00%

Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149

Benzinga·09/17/2026 15:06:05
Listen to the news
Lake Street analyst Daniel Brims initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Buy rating and announces Price Target of $149.